Literature DB >> 7108408

Hypothalamic, pituitary and uterine cytoplasmic and nuclear oestrogen receptors and their relationship to the serum concentration of tamoxifen and its metabolite, 4-hydroxytamoxifen, in the ovariectomized rat.

S P Bowman, A Leake, I D Morris.   

Abstract

High-affinity oestrogen receptors were measured in the cytosol and nuclei prepared from the hypothalamus, pituitary gland and uterus of the ovariectomized rat up to 16 days after a single dose of tamoxifen or 4-hydroxytamoxifen. Tamoxifen produced a dose-related fall in the concentration of cytosol receptors in the hypothalamus, pituitary gland and uterus. Minimum values were observed after 24 h; cytosol receptor concentrations were restored slowly and only reached expected control values between 4 and 8 days and 2 and 4 days for 7.0 mg/kg and 0.7 mg/kg doses of tamoxifen respectively. The nuclear receptor changes were inversely related to the cytosol receptor changes, except that hypothalamic nuclear receptor concentrations after 0.7 mg tamoxifen/kg were not changed. 4-Hydroxytamoxifen (0.14 mg/kg) depleted cytosol and raised nuclear oestrogen receptors in the pituitary gland and uterus. Receptor concentrations had returned to the expected control values by day 4. Oestrogen receptor concentrations in the hypothalamus were unchanged. The apparent resistance of the receptor system in the hypothalamus to translocation by tamoxifen and 4-hydroxytamoxifen was probably due to the blood-brain barrier since the apparent affinity of tamoxifen for the cytosol receptor was similar for all three tissues (dissociation constant 4 nmol/l). Serum concentrations of tamoxifen and 4-hydroxytamoxifen measured after a single dose of 7.0 mg tamoxifen/kg were maximal after 24 h and undetectable by 4 days, at which time nuclear and cytosol receptor levels were still changed. Concentrations of 4-hydroxytamoxifen were approximately one-third those of tamoxifen. The results suggest that the receptor changes after tamoxifen are not simply related to the serum concentration of tamoxifen and its metabolites and that the retention of ligand within the target tissue may be an important determinant.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108408     DOI: 10.1677/joe.0.0940167

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Modification of the rat uterine response to oestrogen and tamoxifen by thromboxane antagonists.

Authors:  M B Kerr; K Marshall; J Senior
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

2.  Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

Authors:  Ksenya Shchors; Anders I Persson; Fanya Rostker; Tarik Tihan; Natalya Lyubynska; Nan Li; Lamorna Brown Swigart; Mitchel S Berger; Douglas Hanahan; William A Weiss; Gerard I Evan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-29       Impact factor: 11.205

3.  Longterm remission of multiple brain metastases with tamoxifen.

Authors:  H Pors; F E von Eyben; O S Sørensen; M Larsen
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

4.  A study on the effect of a single dose of tamoxifen on uterine hyperaemia and growth in the rat.

Authors:  K Marshall; J Senior
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

5.  The biological activity of a single dose of tamoxifen in the adult ovariectomized rat.

Authors:  S P Bowman; C A Jones; A Leake; I D Morris
Journal:  Br J Pharmacol       Date:  1983-04       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.